Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.

ABSTRACT: Immune checkpoint inhibitors (ICI) are a novel class of antineoplastic treatment that enhances immunity against tumors. They are associated with immune adverse events, and several neurological syndromes have been described, including multiple sclerosis and atypical demyelination. We performed a systematic literature review of case reports with neurological immune adverse events that presented with central nervous system demyelination, up to December 2019. We found 23 cases: seven with myelitis, four isolated optic neuritis, one neuromyelitis optica spectrum disorder, five multiple sclerosis, and six with atypical demyelination. Ipilimumab was the most frequently used ICI (11/23). The median time to develop symptoms from the onset of ICI was 6.5 weeks [range 1.0-43.0], and from last ICI dos

SUBMITTER: Oliveira MCB 

PROVIDER: S-EPMC7759512 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature